MX2022001020A - Composicion y metodo para promover la cicatrizacion de heridas. - Google Patents
Composicion y metodo para promover la cicatrizacion de heridas.Info
- Publication number
- MX2022001020A MX2022001020A MX2022001020A MX2022001020A MX2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A
- Authority
- MX
- Mexico
- Prior art keywords
- wound healing
- composition
- promote wound
- construct
- promote
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962879717P | 2019-07-29 | 2019-07-29 | |
| PCT/US2020/043813 WO2021021774A1 (en) | 2019-07-29 | 2020-07-28 | Composition and method for promoting wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001020A true MX2022001020A (es) | 2022-04-06 |
Family
ID=72047146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001020A MX2022001020A (es) | 2019-07-29 | 2020-07-28 | Composicion y metodo para promover la cicatrizacion de heridas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220265759A1 (enExample) |
| EP (1) | EP4003393A1 (enExample) |
| JP (1) | JP7636812B2 (enExample) |
| KR (1) | KR20220042200A (enExample) |
| CA (1) | CA3148980A1 (enExample) |
| MX (1) | MX2022001020A (enExample) |
| WO (1) | WO2021021774A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116121305B (zh) * | 2023-01-03 | 2024-11-22 | 广州医科大学附属第五医院 | 间充质干细胞在糖尿病相关疾病中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| JPS6229997A (ja) | 1985-04-08 | 1987-02-07 | Sankyo Co Ltd | Ｃ末端にプロリンアミドを有するペプチドの製法 |
| US4978532A (en) | 1989-08-11 | 1990-12-18 | Pharmedic Co. | Dosage form for administration of dehydroepiandrosterone |
| US5580751A (en) | 1990-09-14 | 1996-12-03 | Carlsberg A/S | Process for the preparation of C-terminally amidated peptides |
| WO1993002697A1 (en) | 1991-08-08 | 1993-02-18 | Amylin Pharmaceuticals, Inc. | Production of peptide amides |
| DE69332197T2 (de) | 1992-03-13 | 2003-04-17 | Organon Teknika B.V., Boxtel | Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten |
| US5709878A (en) | 1996-08-02 | 1998-01-20 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| GB9708918D0 (en) | 1997-05-01 | 1997-06-25 | Ppl Therapeutics Scotland Ltd | Methods |
| AUPP697698A0 (en) * | 1998-11-06 | 1998-12-03 | St. Vincent's Institute Of Medical Research | Regulation of enzyme activity |
| EP1553973A4 (en) * | 2002-08-16 | 2006-03-01 | Schering Ag | MUTANTS OF ENOS USEFUL FOR GENE THERAPY |
| ES2637956T3 (es) | 2003-01-24 | 2017-10-18 | Stiefel Research Australia Pty Ltd | Espuma farmacéutica |
| AU2006259408A1 (en) | 2005-06-17 | 2006-12-28 | Genentech, Inc. | Use of VEGF for wound healing |
| AU2007293475A1 (en) * | 2006-05-31 | 2008-03-13 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating complications of pregnancy |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009012435A1 (en) * | 2007-07-19 | 2009-01-22 | The Trustees Of The University Of Pennsylvania | Conformational entropy in molecular recognition |
| WO2011062155A1 (ja) * | 2009-11-19 | 2011-05-26 | タカラバイオ株式会社 | 変異型Ｇａｇタンパク質をコードする核酸 |
-
2020
- 2020-07-28 JP JP2022506461A patent/JP7636812B2/ja active Active
- 2020-07-28 KR KR1020227006955A patent/KR20220042200A/ko active Pending
- 2020-07-28 MX MX2022001020A patent/MX2022001020A/es unknown
- 2020-07-28 CA CA3148980A patent/CA3148980A1/en active Pending
- 2020-07-28 WO PCT/US2020/043813 patent/WO2021021774A1/en not_active Ceased
- 2020-07-28 US US17/628,353 patent/US20220265759A1/en active Pending
- 2020-07-28 EP EP20754570.8A patent/EP4003393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7636812B2 (ja) | 2025-02-27 |
| EP4003393A1 (en) | 2022-06-01 |
| WO2021021774A1 (en) | 2021-02-04 |
| CA3148980A1 (en) | 2021-02-04 |
| KR20220042200A (ko) | 2022-04-04 |
| JP2022543056A (ja) | 2022-10-07 |
| US20220265759A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013583A (es) | Anticuerpos il-11. | |
| CL2021000751A1 (es) | Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap | |
| MX2020013468A (es) | Anticuerpos il-11ra. | |
| BR112020015308A8 (pt) | Proteínas f de rsv estabilizadas e usos das mesmas | |
| HN2010001435A (es) | Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion | |
| AR092118A1 (es) | Cepa de bacillus sp. con actividad antifungica, antibacteriana y promotora del crecimiento | |
| EA201170349A1 (ru) | Модуляторы mif | |
| CO6751274A2 (es) | Tratamiento de la osteoartritis y del dolor | |
| CL2009001032A1 (es) | Combinaciones de compuestos activos para controlar plagas animales; uso de las combinaciones; y procedimientos para controlar plagas animales. | |
| MX2013010360A (es) | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. | |
| CL2016000106A1 (es) | Sulfonamidas como moduladores de canales de sodio. | |
| EA201100302A1 (ru) | Лечение диабета у пациентов, для которых лечение метформином является неприемлемым | |
| CO2017004808A2 (es) | Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros | |
| CO2019009612A2 (es) | Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas | |
| EA201391489A1 (ru) | Композиции со сниженной вязкостью | |
| MX2013002255A (es) | Moduladores de proteina de notum y metodos de uso. | |
| CO6300844A2 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
| CR20120052A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
| CR11423A (es) | NUEVOS INHIBIDORES DE sEH Y SU USO | |
| MX2018003337A (es) | Expresion de proteinas recombinantes en pupas de trichoplusia ni. | |
| CO2022002898A2 (es) | Composiciones que comprenden tigolaner para el control de parásitos | |
| MX386250B (es) | Formulaciones novedosas. | |
| CY1125043T1 (el) | Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης | |
| MX2020008034A (es) | Composicion de tinta bilogica para lamina para la regeneracion de la dermis, metodo de fabricacion de lamina personalizada para regeneracion de la dermis usando la misma, y lamina personalizada para regeneracion de la dermis fabricada con el metodo de fabricacion. | |
| CL2021002992A1 (es) | Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa) |